Zymeworks Q3 net loss $47.8M; announces zanidatamab deal with Jazz up to $1.76B

Zymeworks Inc.

2022-Q3 EPS reported -$2.86 revenue$9,989,000

Licensed zanidatamab to Jazz for up to $1.76B total payments plus 10-20% tiered royalties; $50M upfront expected 4Q22.
Q3 revenue $2.6M (down from $4.4M), net loss $47.8M (vs $60.6M YoY).
Cash $166.2M; Jazz upfront extends cash runway through at least 2026.
Phase 1 zanidatamab zovodotin showed 31% ORR at 2.5 mg/kg Q3W; manageable tolerability.
Aims to file 5 INDs in next 5 years; IND for ZW191 (FRα-ADC) expected 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Zymeworks Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

today reported financial results for the third quarter ended September 30, 2022.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-22-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.